Vertex Pharmaceuticals | أصول متداولة



Current Assets تغيير تاريخ
AbbVie USD 25.58B 2.2B 2024-12
Acadia Pharmaceuticals USD 938.32M 150.03M 2024-12
Agios Pharmaceuticals USD 968.62M 3.02M 2025-03
Alnylam Pharmaceuticals USD 3.27B 27.03M 2025-03
Amgen USD 26.93B 2.1B 2025-03
Arrowhead Research USD 570.54M 124.93M 2024-12
Biogen USD 7.63B 169.2M 2025-03
BioMarin Pharmaceutical USD 3.47B 235.48M 2025-03
Bristol-Myers Squibb USD 30.78B 1B 2025-03
Gilead Sciences USD 19.17B 4.39B 2024-12
Incyte USD 3.23B 7.24M 2025-03
Insmed USD 1.62B 28.18M 2024-12
Ionis Pharmaceuticals USD 2.42B 201.36M 2025-03
J&J USD 71.55B 15.66B 2025-03
Merck USD 35.5B 3.28B 2025-03
Moderna USD 6.77B 1.33B 2025-03
Neurocrine Biosciences USD 1.72B 151.9M 2024-12
Novartis USD 29.7B 1.56B 2024-12
Pfizer USD 45.86B 4.5B 2025-03
PTC Therapeutics USD 1.37B 83.98M 2024-12
Regeneron Pharmaceuticals USD 17.57B 9.64B 2025-03
Roche Holding CHF 40.04B 6.41B 2024-12
Sanofi 44.02B 1.43B 2025-03
Sarepta Therapeutics USD 3.07B 388.09M 2024-12
Ultragenyx Pharmaceutical USD 817.12M 17.52M 2024-12
United Therapeutics USD 3.94B 65.9M 2025-03
Vertex Pharmaceuticals USD 9.6B 207.7M 2024-12



Vertex Pharmaceuticals أصول متداولة - القيم الحالية، والبيانات التاريخية، والتنبؤات والإحصاءات والرسوم البيانية والتقويم الاقتصادي - May 2025.